BRPI0517796A - compostos de imidazo[1,2-a]piridina, bem como processo para preparação, composição e uso dos mesmos - Google Patents
compostos de imidazo[1,2-a]piridina, bem como processo para preparação, composição e uso dos mesmosInfo
- Publication number
- BRPI0517796A BRPI0517796A BRPI0517796-0A BRPI0517796A BRPI0517796A BR PI0517796 A BRPI0517796 A BR PI0517796A BR PI0517796 A BRPI0517796 A BR PI0517796A BR PI0517796 A BRPI0517796 A BR PI0517796A
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- composition
- imidazo
- well
- processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
COMPOSTOS DE IMIDAZO ¢1,2-a! PIRIDINA, BEM COMO PROCESSO PARA PREPARAçãO,COMPOSIçãO E USO DOS MESMOS. A presente invenção refere-se aos novos compostos de imidazo ¢1 ,2-a! piridina da fórmula geral (1) assim como sais farmaceuticamente aceitáveis dos mesmos; em que R1, R2,R3 e R4 são como definidos nas reivindicações. Os compostos têm afinidade específica pelo receptor de GABAA e portanto são úteis no tratamento e prevenção de doenças moduladas por receptores de <244>1 e <244>2 - GABAa. .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04105698 | 2004-11-11 | ||
| PCT/EP2005/055753 WO2006051063A1 (en) | 2004-11-11 | 2005-11-04 | Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0517796A true BRPI0517796A (pt) | 2008-10-28 |
Family
ID=34929843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0517796-0A BRPI0517796A (pt) | 2004-11-11 | 2005-11-04 | compostos de imidazo[1,2-a]piridina, bem como processo para preparação, composição e uso dos mesmos |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20080200473A1 (pt) |
| EP (1) | EP1814880B1 (pt) |
| JP (1) | JP2008519805A (pt) |
| KR (1) | KR20070084026A (pt) |
| CN (1) | CN101065377B (pt) |
| AR (1) | AR051626A1 (pt) |
| AT (1) | ATE421962T1 (pt) |
| AU (1) | AU2005303811A1 (pt) |
| BR (1) | BRPI0517796A (pt) |
| CA (1) | CA2585315A1 (pt) |
| DE (1) | DE602005012598D1 (pt) |
| DK (1) | DK1814880T3 (pt) |
| ES (1) | ES2321858T3 (pt) |
| IL (1) | IL182963A0 (pt) |
| MX (1) | MX2007005611A (pt) |
| NO (1) | NO20072831L (pt) |
| PA (1) | PA8652101A1 (pt) |
| PE (1) | PE20060967A1 (pt) |
| PL (1) | PL1814880T3 (pt) |
| PT (1) | PT1814880E (pt) |
| RU (1) | RU2007121864A (pt) |
| TW (1) | TWI357412B (pt) |
| UY (1) | UY29204A1 (pt) |
| WO (1) | WO2006051063A1 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1483283A4 (en) | 2002-03-13 | 2007-04-11 | Signum Biosciences Inc | MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE |
| CA2601777A1 (en) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| EP1845098A1 (en) * | 2006-03-29 | 2007-10-17 | Ferrer Internacional, S.A. | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands |
| KR101119365B1 (ko) * | 2006-05-31 | 2012-03-07 | 에프. 호프만-라 로슈 아게 | 아릴-4-에틴일-아이속사졸 유도체 |
| JP2010501491A (ja) * | 2006-08-24 | 2010-01-21 | オーストラリアン ヌークリア サイエンス アンド テクノロジー オーガニゼイション | 末梢性ベンゾジアゼピン受容体をターゲッティングするためのフッ化リガンド |
| AU2009239430B2 (en) | 2008-04-21 | 2015-01-22 | Signum Biosciences, Inc. | Compounds, compositions and methods for making the same |
| JP5774982B2 (ja) | 2008-05-19 | 2015-09-09 | サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. | イミダゾ[1,2−a]ピリジン化合物 |
| WO2010045615A2 (en) | 2008-10-16 | 2010-04-22 | Cenomed Biosciences, Llc | Treatment of organophosphate exposure with ocinaplon |
| WO2010064020A1 (en) * | 2008-12-04 | 2010-06-10 | Proximagen Ltd. | Imidazopyridine compounds |
| RU2608611C2 (ru) * | 2009-11-05 | 2017-01-23 | Юниверсити Оф Нотр Дам Дю Лак | СОЕДИНЕНИЯ ИМИДАЗО[1,2-а] ПИРИДИНА, ИХ СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ |
| TW201225957A (en) | 2010-09-17 | 2012-07-01 | Taisho Pharmaceutical Co Ltd | Glycine transporter inhibitor |
| BR112018005208B1 (pt) | 2015-09-17 | 2023-12-12 | Marvin J. Miller | Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana |
| US12282014B2 (en) | 2015-11-19 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers |
| CN106906486B (zh) * | 2017-02-22 | 2018-12-11 | 华南理工大学 | 3-溴-2-苯基-咪唑并[1,2-α]吡啶类衍生物的电化学合成方法 |
| WO2019152437A1 (en) | 2018-01-30 | 2019-08-08 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020081588A1 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Swi/snf family chromatin remodeling complexes and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| AU2021213811A1 (en) | 2020-01-29 | 2022-07-28 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| JP2023512038A (ja) * | 2020-01-29 | 2023-03-23 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| AU2024262043A1 (en) * | 2023-04-24 | 2025-11-20 | Shanghai SIMR Biotechnology Co., Ltd | Imidazopyridine or imidazopyrazine compound, preparation method therefor, and pharmaceutical composition and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2568880B1 (fr) * | 1984-08-07 | 1986-12-12 | Synthelabo | Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique |
| ES2032455T3 (es) * | 1986-01-22 | 1993-02-16 | Synthelabo | Procedimiento para preparar derivados de 3-acilaminometil-imidazo (-1,2-a)piridinas. |
| FR2593818B1 (fr) * | 1986-02-05 | 1988-04-29 | Synthelabo | Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique |
| FR2593181B1 (fr) * | 1986-01-22 | 1988-04-01 | Synthelabo | Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique |
| US20040204443A1 (en) * | 2003-01-27 | 2004-10-14 | Arthur Zaks | Method for inducing pain relief using imidazo[1,2-a]pyridine derivatives |
-
2005
- 2005-11-04 BR BRPI0517796-0A patent/BRPI0517796A/pt not_active IP Right Cessation
- 2005-11-04 CA CA002585315A patent/CA2585315A1/en not_active Abandoned
- 2005-11-04 EP EP05808135A patent/EP1814880B1/en not_active Expired - Lifetime
- 2005-11-04 CN CN2005800386913A patent/CN101065377B/zh not_active Expired - Fee Related
- 2005-11-04 AT AT05808135T patent/ATE421962T1/de active
- 2005-11-04 US US11/667,494 patent/US20080200473A1/en not_active Abandoned
- 2005-11-04 ES ES05808135T patent/ES2321858T3/es not_active Expired - Lifetime
- 2005-11-04 RU RU2007121864/04A patent/RU2007121864A/ru not_active Application Discontinuation
- 2005-11-04 AU AU2005303811A patent/AU2005303811A1/en not_active Abandoned
- 2005-11-04 KR KR1020077010318A patent/KR20070084026A/ko not_active Ceased
- 2005-11-04 WO PCT/EP2005/055753 patent/WO2006051063A1/en not_active Ceased
- 2005-11-04 PL PL05808135T patent/PL1814880T3/pl unknown
- 2005-11-04 JP JP2007540634A patent/JP2008519805A/ja active Pending
- 2005-11-04 DE DE602005012598T patent/DE602005012598D1/de not_active Expired - Lifetime
- 2005-11-04 DK DK05808135T patent/DK1814880T3/da active
- 2005-11-04 PT PT05808135T patent/PT1814880E/pt unknown
- 2005-11-04 MX MX2007005611A patent/MX2007005611A/es active IP Right Grant
- 2005-11-07 PE PE2005001302A patent/PE20060967A1/es not_active Application Discontinuation
- 2005-11-08 TW TW094139042A patent/TWI357412B/zh not_active IP Right Cessation
- 2005-11-08 PA PA20058652101A patent/PA8652101A1/es unknown
- 2005-11-09 AR ARP050104693A patent/AR051626A1/es not_active Application Discontinuation
- 2005-11-10 UY UY29204A patent/UY29204A1/es not_active Application Discontinuation
-
2007
- 2007-05-03 IL IL182963A patent/IL182963A0/en unknown
- 2007-06-04 NO NO20072831A patent/NO20072831L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR051626A1 (es) | 2007-01-24 |
| TWI357412B (en) | 2012-02-01 |
| CN101065377A (zh) | 2007-10-31 |
| DE602005012598D1 (de) | 2009-03-19 |
| IL182963A0 (en) | 2007-08-19 |
| PA8652101A1 (es) | 2006-10-13 |
| UY29204A1 (es) | 2006-01-31 |
| US20080200473A1 (en) | 2008-08-21 |
| EP1814880B1 (en) | 2009-01-28 |
| MX2007005611A (es) | 2007-07-11 |
| CA2585315A1 (en) | 2006-05-18 |
| DK1814880T3 (da) | 2009-05-18 |
| WO2006051063A1 (en) | 2006-05-18 |
| NO20072831L (no) | 2007-08-01 |
| EP1814880A1 (en) | 2007-08-08 |
| RU2007121864A (ru) | 2008-12-20 |
| JP2008519805A (ja) | 2008-06-12 |
| KR20070084026A (ko) | 2007-08-24 |
| PE20060967A1 (es) | 2006-09-20 |
| ATE421962T1 (de) | 2009-02-15 |
| TW200624432A (en) | 2006-07-16 |
| ES2321858T3 (es) | 2009-06-12 |
| PT1814880E (pt) | 2009-04-23 |
| PL1814880T3 (pl) | 2009-07-31 |
| AU2005303811A1 (en) | 2006-05-18 |
| CN101065377B (zh) | 2011-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0517796A (pt) | compostos de imidazo[1,2-a]piridina, bem como processo para preparação, composição e uso dos mesmos | |
| CL2008001357A1 (es) | Compuestos derivados de imidazo[4,5-c]quinolina, moduladores de tlr7; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar enfermedades virales, cancer, alergias, infecciones bacterianas, dermatosis, entre otras. | |
| BRPI0510410A (pt) | compostos orgánicos | |
| BRPI0514750A (pt) | derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase | |
| BRPI0514841A (pt) | inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores | |
| BRPI0407811A (pt) | composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso | |
| BRPI0407976A (pt) | tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6 | |
| BRPI0809998B8 (pt) | composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas | |
| BRPI0407507A (pt) | derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona, processos para sua preparação de sua aplicação como medicamento | |
| BR0317268A (pt) | Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos | |
| BR112012017269A2 (pt) | compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos | |
| BRPI0810064B8 (pt) | compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos | |
| BRPI0407387A (pt) | Derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona substituìdos por nitrogênio, processos para a sua preparação e sua aplicação com medicamento | |
| WO2007140385A3 (en) | Thiazole compounds as cannabinoid receptor ligands and uses thereof | |
| BRPI0609719B8 (pt) | derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2 | |
| BR0108841A (pt) | Derivado de pirimidina, processo para prepapar o mesmo, composição farmacêutica, uso de um derivado de pirimidina, e, método para produzir um efeito inibidor do ciclo celular, antic ncer (anti-proliferação celular) em um animal de sangue quente | |
| BRPI0712631B8 (pt) | compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações | |
| CY1109722T1 (el) | Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole | |
| BRPI0414948A (pt) | derivados de pirazolo-e-imidazo pirimidina | |
| BRPI0410238A (pt) | compostos orgánicos | |
| ECSP13012852A (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a. | |
| BRPI0410660A (pt) | derivados de 2-amino-piridina como agonistas de adrenoreceptor ß2 | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| BR112014003063A2 (pt) | "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com ciclopenta[c]pirrol antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso". | |
| BRPI0510412A (pt) | compostos orgánicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |